Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities
- PMID: 22044694
- PMCID: PMC3273617
- DOI: 10.1158/1940-6207.CAPR-11-0306
Randomized, double-blind, placebo-controlled trial of polyphenon E in prostate cancer patients before prostatectomy: evaluation of potential chemopreventive activities
Abstract
Compelling preclinical and pilot clinical data support the role of green tea polyphenols in prostate cancer prevention. We conducted a randomized, double-blind, placebo-controlled trial of polyphenon E (enriched green tea polyphenol extract) in men with prostate cancer scheduled to undergo radical prostatectomy. The study aimed to determine the bioavailability of green tea polyphenols in prostate tissue and to measure its effects on systemic and tissue biomarkers of prostate cancer carcinogenesis. Participants received either polyphenon E (containing 800 mg epigallocatechin gallate) or placebo daily for 3 to 6 weeks before surgery. Following the intervention, green tea polyphenol levels in the prostatectomy tissue were low to undetectable. Polyphenon E intervention resulted in favorable but not statistically significant changes in serum prostate-specific antigen, serum insulin-like growth factor axis, and oxidative DNA damage in blood leukocytes. Tissue biomarkers of cell proliferation, apoptosis, and angiogenesis in the prostatectomy tissue did not differ between the treatment arms. The proportion of subjects who had a decrease in Gleason score between biopsy and surgical specimens was greater in those on polyphenon E but was not statistically significant. The study's findings of low bioavailability and/or bioaccumulation of green tea polyphenols in prostate tissue and statistically insignificant changes in systemic and tissue biomarkers from 3 to 6 weeks of administration suggests that prostate cancer preventive activity of green tea polyphenols, if occurring, may be through indirect means and/or that the activity may need to be evaluated with longer intervention durations, repeated dosing, or in patients at earlier stages of the disease.
Trial registration: ClinicalTrials.gov NCT00459407.
©2011 AACR.
Figures
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3273617/bin/nihms-336373-f0001.gif)
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3273617/bin/nihms-336373-f0002.gif)
Similar articles
-
Results of a phase II randomized, double-blind, placebo-controlled trial of Polyphenon E in women with persistent high-risk HPV infection and low-grade cervical intraepithelial neoplasia.Gynecol Oncol. 2014 Feb;132(2):377-82. doi: 10.1016/j.ygyno.2013.12.034. Epub 2014 Jan 2. Gynecol Oncol. 2014. PMID: 24388920 Free PMC article. Clinical Trial.
-
Green tea polyphenols for prostate cancer chemoprevention: a translational perspective.Phytomedicine. 2010 Jan;17(1):3-13. doi: 10.1016/j.phymed.2009.09.011. Phytomedicine. 2010. PMID: 19959000 Free PMC article. Review.
-
Effects of dosing condition on the oral bioavailability of green tea catechins after single-dose administration of Polyphenon E in healthy individuals.Clin Cancer Res. 2005 Jun 15;11(12):4627-33. doi: 10.1158/1078-0432.CCR-04-2549. Clin Cancer Res. 2005. PMID: 15958649 Clinical Trial.
-
Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals.Clin Cancer Res. 2003 Aug 15;9(9):3312-9. Clin Cancer Res. 2003. PMID: 12960117 Clinical Trial.
-
Chemoprevention of nonmelanoma skin cancer: experience with a polyphenol from green tea.Recent Results Cancer Res. 2003;163:165-71; discussion 264-6. doi: 10.1007/978-3-642-55647-0_15. Recent Results Cancer Res. 2003. PMID: 12903852 Review.
Cited by
-
Recent advances in flavonoid compounds for the treatment of prostate cancer.Mol Biol Rep. 2024 May 11;51(1):653. doi: 10.1007/s11033-024-09567-6. Mol Biol Rep. 2024. PMID: 38734766 Review.
-
Inhibition of Cancer Development by Natural Plant Polyphenols: Molecular Mechanisms.Int J Mol Sci. 2023 Jun 26;24(13):10663. doi: 10.3390/ijms241310663. Int J Mol Sci. 2023. PMID: 37445850 Free PMC article. Review.
-
Current Understanding of Flavonoids in Cancer Therapy and Prevention.Metabolites. 2023 Mar 27;13(4):481. doi: 10.3390/metabo13040481. Metabolites. 2023. PMID: 37110140 Free PMC article. Review.
-
Potential Treatment Options for Neuroblastoma with Polyphenols through Anti-Proliferative and Apoptotic Mechanisms.Biomolecules. 2023 Mar 20;13(3):563. doi: 10.3390/biom13030563. Biomolecules. 2023. PMID: 36979499 Free PMC article. Review.
-
Effects of Green Tea Catechins on Prostate Cancer Chemoprevention: The Role of the Gut Microbiome.Cancers (Basel). 2022 Aug 18;14(16):3988. doi: 10.3390/cancers14163988. Cancers (Basel). 2022. PMID: 36010981 Free PMC article. Review.
References
-
- Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–24. - PubMed
-
- Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med. 2010;362:1192–202. - PubMed
-
- Hamilton RJ, Kahwati LC, Kinsinger LS. Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:2164–71. - PubMed
-
- Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor-I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res. 2004;64:8715–22. - PubMed
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Medical